The pitch sounds almost too neat: strap on a VR headset at home, play through immersive game scenarios, and emerge with better focus and impulse control. But that's precisely what a small team in Regensburg believes they can deliver—and they've just secured €2 million to prove it.
brainjo, a university spin-out from OTH Regensburg, announced the seed round in April, with High-Tech Gründerfonds taking the lead and a handful of business angels—including Andreas Weinhut and investors from better ventures—rounding out the raise. The startup is chasing what it calls a first: a virtual reality-based digital therapeutic specifically designed for children with ADHD, navigating Germany's increasingly rigorous DiGA regulatory pathway.
It's an ambitious goal, perhaps more so than the founders initially imagined. Germany's DiGA framework—which allows doctors to prescribe certified digital health apps with full insurance reimbursement—has been tightening its standards. In 2026, regulators raised the bar for demonstrating real healthcare impact, introducing performance-linked reimbursement models and heightened evidence standards. As of April 2026, 58 applications had made it into the official directory.
Money for a Multi-Year Clinical Gauntlet
The fresh capital will fund what brainjo needs most: a clinical study and the bureaucratic marathon toward regulatory clearance. According to recruitment materials, the trial will enroll roughly 100 children for 12 weeks of at-home VR therapy sessions. Enrollment was slated to begin sometime around the autumn or winter of 2025 into 2026—a timeline that suggests the study may now be underway or ramping up, though the company hasn't disclosed enrollment numbers publicly.
The interdisciplinary team—about ten people at last count—is operating out of the university's facilities, a common setup for German deep-tech spin-outs. Founded in 2022, though with early activities dating back to 2019, they're building what they describe as an immersive therapy platform meant to work alongside traditional psychotherapy, not replace it. The idea: translate therapeutic principles into game-inspired VR scenarios that mirror real-world situations, increasing adherence where conventional approaches sometimes falter.
Whether kids will actually stick with it—and whether clinicians will buy in—remains an open question. VR therapy for mental health has seen mixed results in other contexts, and pediatric applications introduce additional complexity around screen time, motion sickness, and developmental appropriateness.
A Pharma Partner in the Mix
brainjo isn't going it alone. The startup has partnered with MEDICE – The Health Family, a pharmaceutical company that specializes in ADHD treatments. MEDICE's involvement adds both credibility and industry know-how, though the exact nature of the relationship is somewhat opaque. While brainjo's LinkedIn announcement referred to "strategic investors like MEDICE," official press materials from HTGF describe MEDICE as a collaborator rather than explicitly naming them as an equity stakeholder. It's unclear whether MEDICE has put money into the round or simply signed on as a development partner—a distinction that matters when evaluating the startup's financial runway and strategic support.
The company's corporate page confirms the collaboration, framing it as a joint effort to develop "VR game realities" for ADHD. That phrasing—VR game realities—captures the delicate balance brainjo is trying to strike: therapeutic rigor wrapped in engaging gameplay.
2028 or Bust
brainjo is eyeing 2028 for market approval and full DiGA reimbursement, a timeline that reflects just how long the clinical and regulatory slog can take. Even with a successful trial, the startup will need to demonstrate not just efficacy but also cost-effectiveness and real-world impact—standards that Germany's health insurers and regulators are increasingly insistent on.
The company isn't starting from scratch financially. It raised €1.05 million in pre-seed funding in early 2024, supplemented by €650,000 in European and federal grant support. That earlier money presumably funded prototype development and initial validation work. Now, with a larger war chest, the real test begins: proving that virtual reality can do more than entertain, that it can genuinely help children manage a complex neurodevelopmental condition.
If brainjo succeeds, it could carve out a meaningful niche in Germany's expanding digital health ecosystem. If it stumbles—on clinical endpoints, regulatory hurdles, or user adoption—it will join a growing list of digital therapeutics that promised transformation but couldn't quite deliver. For now, the team in Regensburg is heads-down, building and testing. The rest is still ahead of them.
